COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study Of Perennial Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00358475
Recruitment Status : Completed
First Posted : July 31, 2006
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):

Brief Summary:
This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc. Typical symptoms are sneezing, nasal congestion and pruritus and rhinorrhea.

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Seasonal Drug: GW685698 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Perennial Allergic Rhinitis -Long Term Treatment Study-
Study Start Date : June 21, 2005
Actual Primary Completion Date : October 1, 2005
Actual Study Completion Date : October 12, 2005

Primary Outcome Measures :
  1. Adverse events and laboratory blood test

Secondary Outcome Measures :
  1. Change of nasal symptom score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Informed consent.
  • Outpatient.
  • Diagnosis of perennial allergic rhinitis with symptoms.
  • Able to comply with study procedures.

Exclusion criteria:

  • Significant concomitant medical condition.
  • Use of corticosteroids/allergy medications.
  • Laboratory abnormality.
  • Positive pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00358475

Sponsors and Collaborators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline Identifier: NCT00358475    
Other Study ID Numbers: FFR100688
First Posted: July 31, 2006    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Keywords provided by GlaxoSmithKline:
perennial allergic rhinitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases